ESR1 and breast carcinoma: The results showed that patients with ING4-low tumors had more than three times the rate of recurrence and significantly reduced disease-free survival (Figure 5B, HR = 3.22, 95% CI 1.24–5.63, log-rank P = 0.012), demonstrating that low ING4 expression was associated with reduced disease-free survival in ER+ breast cancer.